pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,893 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1894Endpoints1467Fierce Biotech780BioSpace768BioPharma Dive556raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3407Immunology3069Cardiology2875Hematology2338Pulmonology2300Vaccines
  • b.well introduces safety tools for AI health chatbots
    b.well, a startup focusing on patient data, announced new tools aimed at improving safety of AI-driven health chatbots. The tools address concerns that large language models may mishandle personal…
    Endpoints · 5d agoPositive↗ source
  • Fresh & Ready Foods expands recall to include additional Fresh to You sausage, egg & cheese biscuit sandwiches over Listeria risk
    Fresh & Ready Foods announced an expansion of its November 8 recall, now covering additional Fresh to You sausage, egg & cheese biscuit sandwiches made at its Longview, Texas facility. The move fo…
    fda recalls · 5d agoCRLNegative↗ source
← prev
page 3 of 76
next →
126
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Health tech firms eye consumer-driven future at HLTH conference in Las Vegas
    The Endpoints team attended the HLTH conference in Las Vegas despite a ground stop on Friday, gathering insights on health technology trends. Observations suggest the industry is shifting toward c…
    Endpoints · 5d agoNeutral↗ source
  • Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapies
    Eli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
    Endpoints · 6d agoDealPositive↗ source
  • Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns linger
    Helus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…
    Endpoints · 6d agoPositive readoutNegative↗ source
  • Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billion
    Johnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…
    Endpoints · 6d agoDealPositive↗ source
  • Flagship Pioneering invests £100 million to launch AI-focused biotech lab in London
    Flagship Pioneering, the life‑science investor behind Moderna, announced the creation of a new laboratory in London. The lab will concentrate on building AI‑native platform companies, using artifi…
    Endpoints · 6d agoDealPositive↗ source
  • AriBio’s Alzheimer’s trial of repurposed erectile-dysfunction drug shows modest, inconclusive results
    AriBio tested a medication originally approved for erectile dysfunction as a possible therapy for Alzheimer’s disease. The recent Boston‑based study reported only modest signals and failed to show…
    Endpoints · 6d agoNegative readoutNegative↗ source
  • AstraZeneca and Alexion receive FDA nod for Klygefa, a weekly self-administered myasthenia gravis therapy
    AstraZeneca and Alexion announced that the U.S. Food and Drug Administration approved their joint drug Klygefa (gefurulimab) on Monday. Klygefa is a self-administered biologic designed for patient…
    Endpoints · 6d agoApprovalPositive↗ source
  • Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotech
    Eli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…
    Endpoints · 6d agoDealPositive↗ source
  • CG Oncology's oncolytic therapy shows positive Phase 3 results in non-muscle invasive bladder cancer
    CG Oncology announced that its oncolytic immunotherapy, cretostimogene grenadenorepvec, achieved its primary endpoints in a Phase 3 trial involving patients with non-muscle invasive bladder cancer.…
    Endpoints · 6d agoPositive readoutPositive↗ source
  • Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firms
    Sofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
    Endpoints · 6d agoDealPositive↗ source
  • China adds CAR-T therapy to national insurance list, slashing price to $40,000
    China has added a CAR-T therapy to its National Reimbursement Drug List, cutting the price to $40,000. The reduction brings the treatment within the scope of basic medical insurance, improving aff…
    Endpoints · 6d agoRegulatoryNeutral↗ source
  • San Diego’s Seawolf Therapeutics raises $100M to develop non-viral gene therapies for obesity, muscle loss and osteoporosis
    San Diego‑based Seawolf Therapeutics announced it has closed a $100 million financing round to fund its platform for non‑viral gene therapies. The company says its approach tackles a long‑standing…
    Endpoints · 6d agoDealPositive↗ source
  • Parker Institute CEO Karen Knudsen says cancer research faces translation challenges
    Karen Knudsen, who has a track record of reshaping medical organizations, is now leading the Parker Institute for Cancer Immunotherapy, a nonprofit that turned ten years old this year. In a recent…
    Endpoints · 6d agoNeutral↗ source
  • Breckenridge Pharmaceutical recalls one lot of 60 mg propranolol extended-release capsules over possible metal contamination
    Breckenridge Pharmaceutical announced a voluntary recall of a single lot of 60 mg propranolol hydrochloride extended‑release capsules that were produced by Adare Pharma Solutions because of potenti…
    fda recalls · 6d agoCRLNegative↗ source
  • Naia Inc. recalls Chocolate Banana Bar Sorbetto over undeclared milk, egg and pistachio allergens
    Naia Inc., based in Hercules, California, announced a recall of its Chocolate Banana Bar Sorbetto. The recall applies to bars bearing the code dates "BB:Oct/05/2027", "BB:Oct/06/2027", "BB:Oct/07/…
    fda recalls · 6d agoCRLNegative↗ source
  • ALDI recalls Priano protein tortelloni over possible Clostridium botulinum contamination
    ALDI of Batavia, Illinois announced on November 16, 2026 that it is recalling its Priano Protein Carbonara Tortelloni and Priano Protein Herb & Cheese Tortelloni sold at select stores in Alabama, G…
    fda recalls · 6d agoRegulatoryNegative↗ source
  • FDA rejects Summit and Akeso's ivonescimab for narrow lung cancer
    The U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…
    Endpoints · 7d agoRegulatoryNegative↗ source
  • George Church departs AI startup as Ira Mellman advances immunotherapy efforts
    The latest Endpoints Weekly notes that geneticist George Church has left the artificial-intelligence startup he co-founded, signaling a shift in his focus. The newsletter also highlights that immu…
    Endpoints · 8d agoNeutral↗ source
  • Medline recalls all brand beds, rails, mattresses and accessories over fire and entrapment risk
    Medline announced a recall of its entire line of Medline Brand beds, rails, mattresses and related accessories in the United States and Canada. The recall, launched on October 14, 2026, cites a po…
    fda recalls · 9d agoCRLNegative↗ source
  • Moderna says it is ready to produce thousands of doses of its Merck-partnered cancer vaccine ahead of FDA filing
    Moderna announced that it is on track to manufacture large quantities of a cancer vaccine developed in partnership with Merck. The company says production facilities are prepared to produce thousa…
    Endpoints · 9d agoRegulatoryPositive↗ source
  • Argenx CEO Karen Massey drives $3.4 billion of acquisitions to expand beyond Vyvgart
    Argenx, a rare‑disease biotech, announced that under its new CEO Karen Massey it has pursued two acquisitions. The deals together have a potential value of about $3.4 billion and are intended to b…
    Endpoints · 9d agoDealPositive↗ source
  • Milestone Pharmaceuticals trims 20% workforce after FDA approval as Q3 sales reach $1 million
    Milestone Pharmaceuticals announced it is reducing its headcount by about one‑fifth following the recent FDA approval of its heart‑arrhythmia therapy. The cut affects roughly 20% of the company’s s…
    Endpoints · 9d agoLayoffsNegative↗ source
  • AstraZeneca withdraws EU filing for monoclonal antibody targeting amyloidosis subset
    AstraZeneca has announced that it is pulling its European marketing application for a monoclonal antibody intended for a specific subgroup of amyloidosis patients. The decision follows earlier fail…
    Endpoints · 9d agoRegulatoryNegative↗ source